nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—SRC—urinary bladder cancer	0.356	1	CbGaD
Dasatinib—ABCB1—Mitomycin—urinary bladder cancer	0.0231	0.132	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—urinary bladder cancer	0.0189	0.108	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—urinary bladder cancer	0.0158	0.0903	CbGbCtD
Dasatinib—ABCG2—Carboplatin—urinary bladder cancer	0.0157	0.0897	CbGbCtD
Dasatinib—ABCG2—Cisplatin—urinary bladder cancer	0.0134	0.0767	CbGbCtD
Dasatinib—ABCG2—Etoposide—urinary bladder cancer	0.0132	0.0753	CbGbCtD
Dasatinib—CYP3A4—Thiotepa—urinary bladder cancer	0.0105	0.06	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—urinary bladder cancer	0.00898	0.0514	CbGbCtD
Dasatinib—ABCG2—Methotrexate—urinary bladder cancer	0.0087	0.0498	CbGbCtD
Dasatinib—CYP3A5—Etoposide—urinary bladder cancer	0.0073	0.0417	CbGbCtD
Dasatinib—ABCB1—Gemcitabine—urinary bladder cancer	0.00665	0.038	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—urinary bladder cancer	0.00651	0.0372	CbGbCtD
Dasatinib—CYP1A2—Etoposide—urinary bladder cancer	0.00543	0.0311	CbGbCtD
Dasatinib—ABCB1—Cisplatin—urinary bladder cancer	0.00483	0.0276	CbGbCtD
Dasatinib—ABCB1—Etoposide—urinary bladder cancer	0.00475	0.0272	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00324	0.0185	CbGbCtD
Dasatinib—ABCB1—Methotrexate—urinary bladder cancer	0.00314	0.0179	CbGbCtD
Dasatinib—CYP3A4—Etoposide—urinary bladder cancer	0.00285	0.0163	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00194	0.0111	CbGbCtD
Dasatinib—PKMYT1—female reproductive system—urinary bladder cancer	0.000719	0.00564	CbGeAlD
Dasatinib—RIPK2—prostate gland—urinary bladder cancer	0.000716	0.00561	CbGeAlD
Dasatinib—TESK1—seminal vesicle—urinary bladder cancer	0.000712	0.00558	CbGeAlD
Dasatinib—STK36—seminal vesicle—urinary bladder cancer	0.0007	0.00549	CbGeAlD
Dasatinib—SIK1—prostate gland—urinary bladder cancer	0.000699	0.00548	CbGeAlD
Dasatinib—EPHA4—prostate gland—urinary bladder cancer	0.000692	0.00542	CbGeAlD
Dasatinib—ERBB3—prostate gland—urinary bladder cancer	0.000685	0.00537	CbGeAlD
Dasatinib—MAP3K2—prostate gland—urinary bladder cancer	0.000678	0.00532	CbGeAlD
Dasatinib—BMPR1B—epithelium—urinary bladder cancer	0.000671	0.00526	CbGeAlD
Dasatinib—TXK—female reproductive system—urinary bladder cancer	0.000664	0.00521	CbGeAlD
Dasatinib—PTK6—female reproductive system—urinary bladder cancer	0.000657	0.00515	CbGeAlD
Dasatinib—CSK—seminal vesicle—urinary bladder cancer	0.000652	0.00511	CbGeAlD
Dasatinib—PKMYT1—vagina—urinary bladder cancer	0.00065	0.0051	CbGeAlD
Dasatinib—HCK—seminal vesicle—urinary bladder cancer	0.000644	0.00505	CbGeAlD
Dasatinib—MAPK14—prostate gland—urinary bladder cancer	0.000638	0.005	CbGeAlD
Dasatinib—ZAK—urethra—urinary bladder cancer	0.000637	0.005	CbGeAlD
Dasatinib—FGR—prostate gland—urinary bladder cancer	0.000635	0.00498	CbGeAlD
Dasatinib—LCK—prostate gland—urinary bladder cancer	0.000635	0.00498	CbGeAlD
Dasatinib—TEC—lymph node—urinary bladder cancer	0.000622	0.00488	CbGeAlD
Dasatinib—STAT5B—female reproductive system—urinary bladder cancer	0.000622	0.00487	CbGeAlD
Dasatinib—CYP1A2—urine—urinary bladder cancer	0.000617	0.00484	CbGeAlD
Dasatinib—FMO3—prostate gland—urinary bladder cancer	0.000613	0.00481	CbGeAlD
Dasatinib—RIPK2—seminal vesicle—urinary bladder cancer	0.000605	0.00474	CbGeAlD
Dasatinib—EPHB4—prostate gland—urinary bladder cancer	0.000605	0.00474	CbGeAlD
Dasatinib—TXK—vagina—urinary bladder cancer	0.000601	0.00471	CbGeAlD
Dasatinib—JAK2—prostate gland—urinary bladder cancer	0.0006	0.00471	CbGeAlD
Dasatinib—PTK6—vagina—urinary bladder cancer	0.000595	0.00466	CbGeAlD
Dasatinib—EPHA2—prostate gland—urinary bladder cancer	0.000593	0.00465	CbGeAlD
Dasatinib—FYN—prostate gland—urinary bladder cancer	0.000592	0.00464	CbGeAlD
Dasatinib—MAP3K3—prostate gland—urinary bladder cancer	0.000579	0.00454	CbGeAlD
Dasatinib—MAP4K5—prostate gland—urinary bladder cancer	0.000579	0.00454	CbGeAlD
Dasatinib—TESK1—renal system—urinary bladder cancer	0.000574	0.0045	CbGeAlD
Dasatinib—TESK1—urethra—urinary bladder cancer	0.000563	0.00442	CbGeAlD
Dasatinib—SIK3—female reproductive system—urinary bladder cancer	0.000559	0.00438	CbGeAlD
Dasatinib—EPHB3—urethra—urinary bladder cancer	0.000554	0.00435	CbGeAlD
Dasatinib—STK36—urethra—urinary bladder cancer	0.000554	0.00435	CbGeAlD
Dasatinib—EPHB6—prostate gland—urinary bladder cancer	0.000553	0.00434	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—urinary bladder cancer	0.000546	0.00428	CbGeAlD
Dasatinib—FGR—seminal vesicle—urinary bladder cancer	0.000537	0.00421	CbGeAlD
Dasatinib—YES1—prostate gland—urinary bladder cancer	0.000534	0.00419	CbGeAlD
Dasatinib—RIPK2—epithelium—urinary bladder cancer	0.000526	0.00412	CbGeAlD
Dasatinib—CSK—renal system—urinary bladder cancer	0.000525	0.00412	CbGeAlD
Dasatinib—PDGFRA—prostate gland—urinary bladder cancer	0.000524	0.00411	CbGeAlD
Dasatinib—ZAK—female reproductive system—urinary bladder cancer	0.00052	0.00407	CbGeAlD
Dasatinib—CSK—urethra—urinary bladder cancer	0.000516	0.00405	CbGeAlD
Dasatinib—SRC—prostate gland—urinary bladder cancer	0.000514	0.00403	CbGeAlD
Dasatinib—EPHB4—seminal vesicle—urinary bladder cancer	0.000511	0.00401	CbGeAlD
Dasatinib—HCK—urethra—urinary bladder cancer	0.00051	0.00399	CbGeAlD
Dasatinib—JAK2—seminal vesicle—urinary bladder cancer	0.000508	0.00398	CbGeAlD
Dasatinib—ERBB3—epithelium—urinary bladder cancer	0.000503	0.00395	CbGeAlD
Dasatinib—EPHA2—seminal vesicle—urinary bladder cancer	0.000502	0.00393	CbGeAlD
Dasatinib—FYN—seminal vesicle—urinary bladder cancer	0.000501	0.00393	CbGeAlD
Dasatinib—MAP3K19—female reproductive system—urinary bladder cancer	0.000498	0.00391	CbGeAlD
Dasatinib—BMPR1B—female reproductive system—urinary bladder cancer	0.000498	0.00391	CbGeAlD
Dasatinib—MAP3K3—seminal vesicle—urinary bladder cancer	0.000489	0.00384	CbGeAlD
Dasatinib—MAP4K5—seminal vesicle—urinary bladder cancer	0.000489	0.00384	CbGeAlD
Dasatinib—TNK2—female reproductive system—urinary bladder cancer	0.000489	0.00383	CbGeAlD
Dasatinib—EPHB1—lymph node—urinary bladder cancer	0.000488	0.00383	CbGeAlD
Dasatinib—RIPK2—urethra—urinary bladder cancer	0.000479	0.00376	CbGeAlD
Dasatinib—SIK1—renal system—urinary bladder cancer	0.000476	0.00373	CbGeAlD
Dasatinib—MAP2K5—prostate gland—urinary bladder cancer	0.000473	0.00371	CbGeAlD
Dasatinib—ZAK—vagina—urinary bladder cancer	0.00047	0.00368	CbGeAlD
Dasatinib—MAPK14—epithelium—urinary bladder cancer	0.000469	0.00367	CbGeAlD
Dasatinib—SIK1—urethra—urinary bladder cancer	0.000468	0.00367	CbGeAlD
Dasatinib—EPHB6—seminal vesicle—urinary bladder cancer	0.000468	0.00367	CbGeAlD
Dasatinib—ERBB3—renal system—urinary bladder cancer	0.000467	0.00366	CbGeAlD
Dasatinib—EPHA4—urethra—urinary bladder cancer	0.000463	0.00363	CbGeAlD
Dasatinib—CSF1R—prostate gland—urinary bladder cancer	0.000462	0.00362	CbGeAlD
Dasatinib—EPHA5—vagina—urinary bladder cancer	0.00046	0.00361	CbGeAlD
Dasatinib—TESK1—female reproductive system—urinary bladder cancer	0.000459	0.0036	CbGeAlD
Dasatinib—STK36—female reproductive system—urinary bladder cancer	0.000452	0.00354	CbGeAlD
Dasatinib—EPHB3—female reproductive system—urinary bladder cancer	0.000452	0.00354	CbGeAlD
Dasatinib—YES1—seminal vesicle—urinary bladder cancer	0.000452	0.00354	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—urinary bladder cancer	0.000452	0.00354	CbGeAlD
Dasatinib—BTK—vagina—urinary bladder cancer	0.000448	0.00352	CbGeAlD
Dasatinib—CYP3A4—urine—urinary bladder cancer	0.000446	0.0035	CbGeAlD
Dasatinib—EPHB4—epithelium—urinary bladder cancer	0.000444	0.00348	CbGeAlD
Dasatinib—JAK2—epithelium—urinary bladder cancer	0.000441	0.00346	CbGeAlD
Dasatinib—CSK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000439	0.108	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Valrubicin—urinary bladder cancer	0.000439	0.108	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Valrubicin—urinary bladder cancer	0.000439	0.108	CbGdCrCtD
Dasatinib—LIMK2—female reproductive system—urinary bladder cancer	0.000437	0.00343	CbGeAlD
Dasatinib—EPHA2—epithelium—urinary bladder cancer	0.000436	0.00342	CbGeAlD
Dasatinib—MAPK14—renal system—urinary bladder cancer	0.000435	0.00341	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—urinary bladder cancer	0.000428	0.00336	CbGeAlD
Dasatinib—FGR—urethra—urinary bladder cancer	0.000425	0.00333	CbGeAlD
Dasatinib—LCK—urethra—urinary bladder cancer	0.000425	0.00333	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—urinary bladder cancer	0.000425	0.00333	CbGeAlD
Dasatinib—STK35—female reproductive system—urinary bladder cancer	0.000424	0.00332	CbGeAlD
Dasatinib—CSK—female reproductive system—urinary bladder cancer	0.000421	0.0033	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—urinary bladder cancer	0.000419	0.00329	CbGeAlD
Dasatinib—KIT—prostate gland—urinary bladder cancer	0.000419	0.00329	CbGeAlD
Dasatinib—TESK1—vagina—urinary bladder cancer	0.000415	0.00326	CbGeAlD
Dasatinib—EPHB4—renal system—urinary bladder cancer	0.000412	0.00323	CbGeAlD
Dasatinib—BMX—lymph node—urinary bladder cancer	0.00041	0.00322	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—urinary bladder cancer	0.00041	0.00321	CbGeAlD
Dasatinib—PDGFRB—prostate gland—urinary bladder cancer	0.000409	0.00321	CbGeAlD
Dasatinib—JAK2—renal system—urinary bladder cancer	0.000409	0.00321	CbGeAlD
Dasatinib—EPHB3—vagina—urinary bladder cancer	0.000409	0.00321	CbGeAlD
Dasatinib—STK36—vagina—urinary bladder cancer	0.000409	0.00321	CbGeAlD
Dasatinib—BLK—lymph node—urinary bladder cancer	0.000406	0.00318	CbGeAlD
Dasatinib—EPHB4—urethra—urinary bladder cancer	0.000405	0.00317	CbGeAlD
Dasatinib—FYN—renal system—urinary bladder cancer	0.000404	0.00316	CbGeAlD
Dasatinib—JAK2—urethra—urinary bladder cancer	0.000402	0.00315	CbGeAlD
Dasatinib—MAP2K5—seminal vesicle—urinary bladder cancer	0.0004	0.00314	CbGeAlD
Dasatinib—EPHA2—urethra—urinary bladder cancer	0.000397	0.00311	CbGeAlD
Dasatinib—FYN—urethra—urinary bladder cancer	0.000396	0.00311	CbGeAlD
Dasatinib—LIMK2—vagina—urinary bladder cancer	0.000395	0.0031	CbGeAlD
Dasatinib—RIPK2—female reproductive system—urinary bladder cancer	0.000391	0.00306	CbGeAlD
Dasatinib—CSF1R—seminal vesicle—urinary bladder cancer	0.00039	0.00306	CbGeAlD
Dasatinib—TXK—lymph node—urinary bladder cancer	0.000388	0.00305	CbGeAlD
Dasatinib—MAP4K5—urethra—urinary bladder cancer	0.000387	0.00304	CbGeAlD
Dasatinib—MAP3K3—urethra—urinary bladder cancer	0.000387	0.00304	CbGeAlD
Dasatinib—STK35—vagina—urinary bladder cancer	0.000383	0.003	CbGeAlD
Dasatinib—SIK1—female reproductive system—urinary bladder cancer	0.000381	0.00299	CbGeAlD
Dasatinib—CSK—vagina—urinary bladder cancer	0.000381	0.00298	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—urinary bladder cancer	0.000378	0.00297	CbGeAlD
Dasatinib—SRC—epithelium—urinary bladder cancer	0.000378	0.00296	CbGeAlD
Dasatinib—EPHA4—female reproductive system—urinary bladder cancer	0.000378	0.00296	CbGeAlD
Dasatinib—HCK—vagina—urinary bladder cancer	0.000376	0.00295	CbGeAlD
Dasatinib—ERBB3—female reproductive system—urinary bladder cancer	0.000374	0.00293	CbGeAlD
Dasatinib—ABL2—vagina—urinary bladder cancer	0.000373	0.00293	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—urinary bladder cancer	0.000371	0.00291	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—urinary bladder cancer	0.00037	0.0029	CbGeAlD
Dasatinib—EPHB6—urethra—urinary bladder cancer	0.00037	0.0029	CbGeAlD
Dasatinib—ABL1—prostate gland—urinary bladder cancer	0.000365	0.00286	CbGeAlD
Dasatinib—YES1—renal system—urinary bladder cancer	0.000364	0.00286	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—urinary bladder cancer	0.000364	0.00285	CbGeAlD
Dasatinib—STAT5B—lymph node—urinary bladder cancer	0.000364	0.00285	CbGeAlD
Dasatinib—YES1—urethra—urinary bladder cancer	0.000358	0.0028	CbGeAlD
Dasatinib—PDGFRA—renal system—urinary bladder cancer	0.000357	0.0028	CbGeAlD
Dasatinib—KIT—seminal vesicle—urinary bladder cancer	0.000354	0.00278	CbGeAlD
Dasatinib—RIPK2—vagina—urinary bladder cancer	0.000353	0.00277	CbGeAlD
Dasatinib—SRC—renal system—urinary bladder cancer	0.00035	0.00275	CbGeAlD
Dasatinib—MAPK14—female reproductive system—urinary bladder cancer	0.000348	0.00273	CbGeAlD
Dasatinib—FGR—female reproductive system—urinary bladder cancer	0.000347	0.00272	CbGeAlD
Dasatinib—PDGFRB—seminal vesicle—urinary bladder cancer	0.000346	0.00271	CbGeAlD
Dasatinib—EPHA4—vagina—urinary bladder cancer	0.000341	0.00268	CbGeAlD
Dasatinib—EPHA3—lymph node—urinary bladder cancer	0.000336	0.00264	CbGeAlD
Dasatinib—EPHB4—female reproductive system—urinary bladder cancer	0.00033	0.00259	CbGeAlD
Dasatinib—JAK2—female reproductive system—urinary bladder cancer	0.000328	0.00257	CbGeAlD
Dasatinib—SIK3—lymph node—urinary bladder cancer	0.000327	0.00256	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.000327	0.00256	CbGeAlD
Dasatinib—EPHA2—female reproductive system—urinary bladder cancer	0.000324	0.00254	CbGeAlD
Dasatinib—FYN—female reproductive system—urinary bladder cancer	0.000323	0.00253	CbGeAlD
Dasatinib—ERBB3—Podofilox—Etoposide—urinary bladder cancer	0.000317	0.0781	CbGdCrCtD
Dasatinib—MAP2K5—urethra—urinary bladder cancer	0.000317	0.00248	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—urinary bladder cancer	0.000316	0.00248	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—urinary bladder cancer	0.000316	0.00248	CbGeAlD
Dasatinib—MAPK14—vagina—urinary bladder cancer	0.000315	0.00247	CbGeAlD
Dasatinib—FGR—vagina—urinary bladder cancer	0.000314	0.00246	CbGeAlD
Dasatinib—LCK—vagina—urinary bladder cancer	0.000314	0.00246	CbGeAlD
Dasatinib—CSF1R—urethra—urinary bladder cancer	0.000309	0.00242	CbGeAlD
Dasatinib—CYP1B1—prostate gland—urinary bladder cancer	0.000309	0.00242	CbGeAlD
Dasatinib—ABL1—seminal vesicle—urinary bladder cancer	0.000309	0.00242	CbGeAlD
Dasatinib—KIT—epithelium—urinary bladder cancer	0.000308	0.00241	CbGeAlD
Dasatinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000306	0.0754	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000306	0.0754	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000306	0.0754	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000306	0.0754	CbGdCrCtD
Dasatinib—ZAK—lymph node—urinary bladder cancer	0.000304	0.00238	CbGeAlD
Dasatinib—FMO3—vagina—urinary bladder cancer	0.000303	0.00237	CbGeAlD
Dasatinib—PDGFRB—epithelium—urinary bladder cancer	0.000301	0.00236	CbGeAlD
Dasatinib—EPHB4—vagina—urinary bladder cancer	0.000298	0.00234	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—urinary bladder cancer	0.000297	0.00233	CbGeAlD
Dasatinib—JAK2—vagina—urinary bladder cancer	0.000296	0.00232	CbGeAlD
Dasatinib—EPHA2—vagina—urinary bladder cancer	0.000293	0.0023	CbGeAlD
Dasatinib—FYN—vagina—urinary bladder cancer	0.000292	0.00229	CbGeAlD
Dasatinib—YES1—female reproductive system—urinary bladder cancer	0.000292	0.00229	CbGeAlD
Dasatinib—BMPR1B—lymph node—urinary bladder cancer	0.000291	0.00228	CbGeAlD
Dasatinib—BTK—lymph node—urinary bladder cancer	0.00029	0.00227	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—urinary bladder cancer	0.00029	0.00227	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—urinary bladder cancer	0.000286	0.00224	CbGeAlD
Dasatinib—TNK2—lymph node—urinary bladder cancer	0.000286	0.00224	CbGeAlD
Dasatinib—MAP4K5—vagina—urinary bladder cancer	0.000286	0.00224	CbGeAlD
Dasatinib—MAP3K3—vagina—urinary bladder cancer	0.000286	0.00224	CbGeAlD
Dasatinib—KIT—renal system—urinary bladder cancer	0.000286	0.00224	CbGeAlD
Dasatinib—SRC—female reproductive system—urinary bladder cancer	0.000281	0.0022	CbGeAlD
Dasatinib—KIT—urethra—urinary bladder cancer	0.000281	0.0022	CbGeAlD
Dasatinib—PDGFRB—renal system—urinary bladder cancer	0.000279	0.00219	CbGeAlD
Dasatinib—PDGFRB—urethra—urinary bladder cancer	0.000274	0.00215	CbGeAlD
Dasatinib—EPHB6—vagina—urinary bladder cancer	0.000273	0.00214	CbGeAlD
Dasatinib—TESK1—lymph node—urinary bladder cancer	0.000269	0.00211	CbGeAlD
Dasatinib—STK36—lymph node—urinary bladder cancer	0.000264	0.00207	CbGeAlD
Dasatinib—EPHB3—lymph node—urinary bladder cancer	0.000264	0.00207	CbGeAlD
Dasatinib—YES1—vagina—urinary bladder cancer	0.000264	0.00207	CbGeAlD
Dasatinib—PDGFRA—vagina—urinary bladder cancer	0.000259	0.00203	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000258	0.00203	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—urinary bladder cancer	0.000258	0.00202	CbGeAlD
Dasatinib—LIMK2—lymph node—urinary bladder cancer	0.000256	0.002	CbGeAlD
Dasatinib—CSF1R—female reproductive system—urinary bladder cancer	0.000252	0.00198	CbGeAlD
Dasatinib—ABL1—renal system—urinary bladder cancer	0.000249	0.00195	CbGeAlD
Dasatinib—STK35—lymph node—urinary bladder cancer	0.000248	0.00194	CbGeAlD
Dasatinib—CSK—lymph node—urinary bladder cancer	0.000246	0.00193	CbGeAlD
Dasatinib—ABL1—urethra—urinary bladder cancer	0.000244	0.00191	CbGeAlD
Dasatinib—HCK—lymph node—urinary bladder cancer	0.000243	0.00191	CbGeAlD
Dasatinib—ABL2—lymph node—urinary bladder cancer	0.000241	0.00189	CbGeAlD
Dasatinib—MAP2K5—vagina—urinary bladder cancer	0.000233	0.00183	CbGeAlD
Dasatinib—ABCG2—prostate gland—urinary bladder cancer	0.00023	0.0018	CbGeAlD
Dasatinib—KIT—female reproductive system—urinary bladder cancer	0.000229	0.00179	CbGeAlD
Dasatinib—RIPK2—lymph node—urinary bladder cancer	0.000228	0.00179	CbGeAlD
Dasatinib—CSF1R—vagina—urinary bladder cancer	0.000228	0.00179	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—urinary bladder cancer	0.000223	0.00175	CbGeAlD
Dasatinib—SIK1—lymph node—urinary bladder cancer	0.000223	0.00175	CbGeAlD
Dasatinib—EPHA4—lymph node—urinary bladder cancer	0.000221	0.00173	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000219	0.00171	CbGeAlD
Dasatinib—ERBB3—lymph node—urinary bladder cancer	0.000219	0.00171	CbGeAlD
Dasatinib—MAP3K2—lymph node—urinary bladder cancer	0.000217	0.0017	CbGeAlD
Dasatinib—CYP3A5—prostate gland—urinary bladder cancer	0.000214	0.00167	CbGeAlD
Dasatinib—CYP1B1—renal system—urinary bladder cancer	0.000211	0.00165	CbGeAlD
Dasatinib—KIT—vagina—urinary bladder cancer	0.000207	0.00162	CbGeAlD
Dasatinib—MAPK14—lymph node—urinary bladder cancer	0.000204	0.0016	CbGeAlD
Dasatinib—FGR—lymph node—urinary bladder cancer	0.000203	0.00159	CbGeAlD
Dasatinib—LCK—lymph node—urinary bladder cancer	0.000203	0.00159	CbGeAlD
Dasatinib—PDGFRB—vagina—urinary bladder cancer	0.000202	0.00158	CbGeAlD
Dasatinib—ABL1—female reproductive system—urinary bladder cancer	0.000199	0.00156	CbGeAlD
Dasatinib—FMO3—lymph node—urinary bladder cancer	0.000196	0.00154	CbGeAlD
Dasatinib—ABCG2—seminal vesicle—urinary bladder cancer	0.000195	0.00153	CbGeAlD
Dasatinib—EPHB4—lymph node—urinary bladder cancer	0.000193	0.00151	CbGeAlD
Dasatinib—JAK2—lymph node—urinary bladder cancer	0.000192	0.0015	CbGeAlD
Dasatinib—EPHA2—lymph node—urinary bladder cancer	0.000189	0.00148	CbGeAlD
Dasatinib—FYN—lymph node—urinary bladder cancer	0.000189	0.00148	CbGeAlD
Dasatinib—MAP4K5—lymph node—urinary bladder cancer	0.000185	0.00145	CbGeAlD
Dasatinib—MAP3K3—lymph node—urinary bladder cancer	0.000185	0.00145	CbGeAlD
Dasatinib—ABL1—vagina—urinary bladder cancer	0.00018	0.00141	CbGeAlD
Dasatinib—EPHB6—lymph node—urinary bladder cancer	0.000177	0.00138	CbGeAlD
Dasatinib—YES1—lymph node—urinary bladder cancer	0.000171	0.00134	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—urinary bladder cancer	0.000169	0.00132	CbGeAlD
Dasatinib—PDGFRA—lymph node—urinary bladder cancer	0.000167	0.00131	CbGeAlD
Dasatinib—SRC—lymph node—urinary bladder cancer	0.000164	0.00129	CbGeAlD
Dasatinib—CYP1A1—epithelium—urinary bladder cancer	0.00016	0.00126	CbGeAlD
Dasatinib—ABCG2—urethra—urinary bladder cancer	0.000154	0.00121	CbGeAlD
Dasatinib—CSK—Daunorubicin—Epirubicin—urinary bladder cancer	0.000153	0.0376	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Epirubicin—urinary bladder cancer	0.000153	0.0376	CbGdCrCtD
Dasatinib—MAP2K5—lymph node—urinary bladder cancer	0.000151	0.00118	CbGeAlD
Dasatinib—CYP1A2—renal system—urinary bladder cancer	0.000151	0.00118	CbGeAlD
Dasatinib—CYP1A1—renal system—urinary bladder cancer	0.000149	0.00117	CbGeAlD
Dasatinib—CSF1R—lymph node—urinary bladder cancer	0.000147	0.00116	CbGeAlD
Dasatinib—CYP1A1—urethra—urinary bladder cancer	0.000146	0.00115	CbGeAlD
Dasatinib—CYP3A5—renal system—urinary bladder cancer	0.000146	0.00114	CbGeAlD
Dasatinib—CSK—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000141	0.0348	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—urinary bladder cancer	0.000141	0.0348	CbGdCrCtD
Dasatinib—KIT—lymph node—urinary bladder cancer	0.000134	0.00105	CbGeAlD
Dasatinib—PDGFRB—lymph node—urinary bladder cancer	0.000131	0.00102	CbGeAlD
Dasatinib—CYP1A1—female reproductive system—urinary bladder cancer	0.000119	0.000935	CbGeAlD
Dasatinib—ABL1—lymph node—urinary bladder cancer	0.000116	0.000913	CbGeAlD
Dasatinib—ABCG2—vagina—urinary bladder cancer	0.000114	0.00089	CbGeAlD
Dasatinib—ABCB1—prostate gland—urinary bladder cancer	0.000113	0.000889	CbGeAlD
Dasatinib—CYP3A4—renal system—urinary bladder cancer	0.000109	0.000856	CbGeAlD
Dasatinib—CYP1A1—vagina—urinary bladder cancer	0.000108	0.000845	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	0.000107	0.0262	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000107	0.0262	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	0.000107	0.0262	CbGdCrCtD
Dasatinib—CYP3A5—vagina—urinary bladder cancer	0.000105	0.000827	CbGeAlD
Dasatinib—CYP1B1—lymph node—urinary bladder cancer	9.87e-05	0.000773	CbGeAlD
Dasatinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	9.86e-05	0.0243	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	9.86e-05	0.0243	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	9.86e-05	0.0243	CbGdCrCtD
Dasatinib—ABCB1—seminal vesicle—urinary bladder cancer	9.6e-05	0.000752	CbGeAlD
Dasatinib—CYP3A4—female reproductive system—urinary bladder cancer	8.75e-05	0.000686	CbGeAlD
Dasatinib—ABCB1—epithelium—urinary bladder cancer	8.34e-05	0.000654	CbGeAlD
Dasatinib—ABCB1—renal system—urinary bladder cancer	7.73e-05	0.000606	CbGeAlD
Dasatinib—ABCB1—urethra—urinary bladder cancer	7.6e-05	0.000595	CbGeAlD
Dasatinib—ABCG2—lymph node—urinary bladder cancer	7.35e-05	0.000576	CbGeAlD
Dasatinib—CYP1A1—lymph node—urinary bladder cancer	6.97e-05	0.000547	CbGeAlD
Dasatinib—Diarrhoea—Gemcitabine—urinary bladder cancer	6.45e-05	0.000412	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—urinary bladder cancer	6.43e-05	0.000411	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—urinary bladder cancer	6.42e-05	0.00041	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	6.42e-05	0.00041	CcSEcCtD
Dasatinib—Urticaria—Etoposide—urinary bladder cancer	6.39e-05	0.000408	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—urinary bladder cancer	6.38e-05	0.000407	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—urinary bladder cancer	6.38e-05	0.000407	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—urinary bladder cancer	6.36e-05	0.000406	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—urinary bladder cancer	6.36e-05	0.000406	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—urinary bladder cancer	6.36e-05	0.000406	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—urinary bladder cancer	6.35e-05	0.000405	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—urinary bladder cancer	6.35e-05	0.000405	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—urinary bladder cancer	6.34e-05	0.000405	CcSEcCtD
Dasatinib—Diarrhoea—Fluorouracil—urinary bladder cancer	6.34e-05	0.000405	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—urinary bladder cancer	6.33e-05	0.000404	CcSEcCtD
Dasatinib—Asthenia—Cisplatin—urinary bladder cancer	6.3e-05	0.000402	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—urinary bladder cancer	6.3e-05	0.000402	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	6.27e-05	0.0004	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—urinary bladder cancer	6.26e-05	0.000399	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—urinary bladder cancer	6.24e-05	0.000398	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	6.24e-05	0.000398	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—urinary bladder cancer	6.22e-05	0.000397	CcSEcCtD
Dasatinib—ABCB1—female reproductive system—urinary bladder cancer	6.19e-05	0.000485	CbGeAlD
Dasatinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	6.19e-05	0.000395	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—urinary bladder cancer	6.17e-05	0.000394	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—urinary bladder cancer	6.16e-05	0.000393	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—urinary bladder cancer	6.13e-05	0.000391	CcSEcCtD
Dasatinib—Dizziness—Fluorouracil—urinary bladder cancer	6.13e-05	0.000391	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—urinary bladder cancer	6.12e-05	0.000391	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	6.11e-05	0.00039	CcSEcCtD
Dasatinib—Chills—Methotrexate—urinary bladder cancer	6.09e-05	0.000389	CcSEcCtD
Dasatinib—Diarrhoea—Cisplatin—urinary bladder cancer	6.01e-05	0.000384	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—urinary bladder cancer	6e-05	0.000383	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—urinary bladder cancer	6e-05	0.000383	CcSEcCtD
Dasatinib—Vomiting—Gemcitabine—urinary bladder cancer	5.99e-05	0.000383	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—urinary bladder cancer	5.94e-05	0.000379	CcSEcCtD
Dasatinib—Rash—Gemcitabine—urinary bladder cancer	5.94e-05	0.000379	CcSEcCtD
Dasatinib—Dermatitis—Gemcitabine—urinary bladder cancer	5.94e-05	0.000379	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—urinary bladder cancer	5.93e-05	0.000379	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—urinary bladder cancer	5.93e-05	0.000379	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—urinary bladder cancer	5.92e-05	0.000378	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—urinary bladder cancer	5.91e-05	0.000377	CcSEcCtD
Dasatinib—Erythema—Methotrexate—urinary bladder cancer	5.91e-05	0.000377	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—urinary bladder cancer	5.9e-05	0.000377	CcSEcCtD
Dasatinib—Headache—Gemcitabine—urinary bladder cancer	5.9e-05	0.000377	CcSEcCtD
Dasatinib—Flushing—Epirubicin—urinary bladder cancer	5.89e-05	0.000376	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—urinary bladder cancer	5.89e-05	0.000376	CcSEcCtD
Dasatinib—Vomiting—Fluorouracil—urinary bladder cancer	5.89e-05	0.000376	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—urinary bladder cancer	5.88e-05	0.000375	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—urinary bladder cancer	5.88e-05	0.000375	CcSEcCtD
Dasatinib—Rash—Fluorouracil—urinary bladder cancer	5.84e-05	0.000373	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—urinary bladder cancer	5.84e-05	0.000373	CcSEcCtD
Dasatinib—Headache—Fluorouracil—urinary bladder cancer	5.81e-05	0.000371	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	5.8e-05	0.00037	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.79e-05	0.000369	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—urinary bladder cancer	5.78e-05	0.000369	CcSEcCtD
Dasatinib—Asthenia—Etoposide—urinary bladder cancer	5.77e-05	0.000369	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.77e-05	0.000369	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—urinary bladder cancer	5.76e-05	0.000368	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—urinary bladder cancer	5.76e-05	0.000368	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—urinary bladder cancer	5.74e-05	0.000366	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.72e-05	0.000365	CcSEcCtD
Dasatinib—Chills—Epirubicin—urinary bladder cancer	5.7e-05	0.000364	CcSEcCtD
Dasatinib—Pruritus—Etoposide—urinary bladder cancer	5.69e-05	0.000363	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—urinary bladder cancer	5.67e-05	0.000362	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—urinary bladder cancer	5.66e-05	0.000361	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—urinary bladder cancer	5.61e-05	0.000358	CcSEcCtD
Dasatinib—ABCB1—vagina—urinary bladder cancer	5.6e-05	0.000439	CbGeAlD
Dasatinib—Nausea—Gemcitabine—urinary bladder cancer	5.6e-05	0.000357	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—urinary bladder cancer	5.59e-05	0.000357	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—urinary bladder cancer	5.57e-05	0.000355	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—urinary bladder cancer	5.56e-05	0.000355	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—urinary bladder cancer	5.55e-05	0.000355	CcSEcCtD
Dasatinib—Rash—Cisplatin—urinary bladder cancer	5.54e-05	0.000354	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—urinary bladder cancer	5.53e-05	0.000353	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—urinary bladder cancer	5.53e-05	0.000353	CcSEcCtD
Dasatinib—Erythema—Epirubicin—urinary bladder cancer	5.53e-05	0.000353	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—urinary bladder cancer	5.51e-05	0.000352	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—urinary bladder cancer	5.5e-05	0.000351	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—urinary bladder cancer	5.49e-05	0.000351	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—urinary bladder cancer	5.48e-05	0.00035	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—urinary bladder cancer	5.48e-05	0.00035	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—urinary bladder cancer	5.46e-05	0.000349	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—urinary bladder cancer	5.45e-05	0.000348	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.45e-05	0.000348	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—urinary bladder cancer	5.41e-05	0.000346	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—urinary bladder cancer	5.33e-05	0.00034	CcSEcCtD
Dasatinib—Malaise—Methotrexate—urinary bladder cancer	5.33e-05	0.00034	CcSEcCtD
Dasatinib—Dizziness—Etoposide—urinary bladder cancer	5.32e-05	0.00034	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—urinary bladder cancer	5.31e-05	0.000339	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—urinary bladder cancer	5.31e-05	0.000339	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—urinary bladder cancer	5.31e-05	0.000339	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	5.29e-05	0.000338	CcSEcCtD
Dasatinib—Chills—Doxorubicin—urinary bladder cancer	5.27e-05	0.000337	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—urinary bladder cancer	5.25e-05	0.000335	CcSEcCtD
Dasatinib—Nausea—Cisplatin—urinary bladder cancer	5.22e-05	0.000333	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—urinary bladder cancer	5.21e-05	0.000333	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—urinary bladder cancer	5.19e-05	0.000331	CcSEcCtD
Dasatinib—Cough—Methotrexate—urinary bladder cancer	5.15e-05	0.000329	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—urinary bladder cancer	5.15e-05	0.000329	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—urinary bladder cancer	5.13e-05	0.000327	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—urinary bladder cancer	5.12e-05	0.000327	CcSEcCtD
Dasatinib—Vomiting—Etoposide—urinary bladder cancer	5.12e-05	0.000327	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—urinary bladder cancer	5.11e-05	0.000327	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—urinary bladder cancer	5.11e-05	0.000327	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—urinary bladder cancer	5.11e-05	0.000326	CcSEcCtD
Dasatinib—Rash—Etoposide—urinary bladder cancer	5.07e-05	0.000324	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—urinary bladder cancer	5.07e-05	0.000324	CcSEcCtD
Dasatinib—Headache—Etoposide—urinary bladder cancer	5.04e-05	0.000322	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—urinary bladder cancer	5.03e-05	0.000321	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—urinary bladder cancer	5.03e-05	0.000321	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—urinary bladder cancer	5.03e-05	0.000321	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—urinary bladder cancer	5.01e-05	0.00032	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.99e-05	0.000319	CcSEcCtD
Dasatinib—Malaise—Epirubicin—urinary bladder cancer	4.98e-05	0.000318	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—urinary bladder cancer	4.97e-05	0.000317	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—urinary bladder cancer	4.97e-05	0.000317	CcSEcCtD
Dasatinib—Syncope—Epirubicin—urinary bladder cancer	4.96e-05	0.000316	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—urinary bladder cancer	4.92e-05	0.000314	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—urinary bladder cancer	4.88e-05	0.000312	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—urinary bladder cancer	4.86e-05	0.00031	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—urinary bladder cancer	4.86e-05	0.00031	CcSEcCtD
Dasatinib—Cough—Epirubicin—urinary bladder cancer	4.82e-05	0.000308	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—urinary bladder cancer	4.82e-05	0.000308	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—urinary bladder cancer	4.79e-05	0.000306	CcSEcCtD
Dasatinib—Infection—Methotrexate—urinary bladder cancer	4.79e-05	0.000306	CcSEcCtD
Dasatinib—Nausea—Etoposide—urinary bladder cancer	4.78e-05	0.000305	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—urinary bladder cancer	4.77e-05	0.000305	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.75e-05	0.000303	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—urinary bladder cancer	4.73e-05	0.000302	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—urinary bladder cancer	4.73e-05	0.000302	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.72e-05	0.000301	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—urinary bladder cancer	4.71e-05	0.0003	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—urinary bladder cancer	4.71e-05	0.0003	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—urinary bladder cancer	4.71e-05	0.0003	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—urinary bladder cancer	4.69e-05	0.000299	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—urinary bladder cancer	4.68e-05	0.000299	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.67e-05	0.000298	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.66e-05	0.000298	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—urinary bladder cancer	4.65e-05	0.000297	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—urinary bladder cancer	4.61e-05	0.000294	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—urinary bladder cancer	4.59e-05	0.000293	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—urinary bladder cancer	4.59e-05	0.000293	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—urinary bladder cancer	4.59e-05	0.000293	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—urinary bladder cancer	4.55e-05	0.00029	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—urinary bladder cancer	4.52e-05	0.000289	CcSEcCtD
Dasatinib—Oedema—Epirubicin—urinary bladder cancer	4.51e-05	0.000288	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—urinary bladder cancer	4.5e-05	0.000288	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—urinary bladder cancer	4.5e-05	0.000287	CcSEcCtD
Dasatinib—Infection—Epirubicin—urinary bladder cancer	4.48e-05	0.000286	CcSEcCtD
Dasatinib—Cough—Doxorubicin—urinary bladder cancer	4.46e-05	0.000285	CcSEcCtD
Dasatinib—Shock—Epirubicin—urinary bladder cancer	4.44e-05	0.000283	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—urinary bladder cancer	4.43e-05	0.000283	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—urinary bladder cancer	4.42e-05	0.000282	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.42e-05	0.000282	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—urinary bladder cancer	4.42e-05	0.000282	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—urinary bladder cancer	4.4e-05	0.000281	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.39e-05	0.00028	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—urinary bladder cancer	4.38e-05	0.00028	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.36e-05	0.000278	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—urinary bladder cancer	4.36e-05	0.000278	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—urinary bladder cancer	4.35e-05	0.000278	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—urinary bladder cancer	4.35e-05	0.000278	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—urinary bladder cancer	4.35e-05	0.000278	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—urinary bladder cancer	4.34e-05	0.000277	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.32e-05	0.000276	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—urinary bladder cancer	4.3e-05	0.000275	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—urinary bladder cancer	4.3e-05	0.000275	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—urinary bladder cancer	4.3e-05	0.000274	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—urinary bladder cancer	4.29e-05	0.000274	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—urinary bladder cancer	4.24e-05	0.000271	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—urinary bladder cancer	4.22e-05	0.000269	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—urinary bladder cancer	4.21e-05	0.000269	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—urinary bladder cancer	4.19e-05	0.000268	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—urinary bladder cancer	4.17e-05	0.000266	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.16e-05	0.000266	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—urinary bladder cancer	4.16e-05	0.000265	CcSEcCtD
Dasatinib—Infection—Doxorubicin—urinary bladder cancer	4.15e-05	0.000265	CcSEcCtD
Dasatinib—Pain—Methotrexate—urinary bladder cancer	4.12e-05	0.000263	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.11e-05	0.000262	CcSEcCtD
Dasatinib—Shock—Doxorubicin—urinary bladder cancer	4.11e-05	0.000262	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.09e-05	0.000261	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.09e-05	0.000261	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—urinary bladder cancer	4.08e-05	0.00026	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—urinary bladder cancer	4.07e-05	0.00026	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—urinary bladder cancer	4.05e-05	0.000259	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.04e-05	0.000258	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—urinary bladder cancer	4.02e-05	0.000257	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—urinary bladder cancer	4.01e-05	0.000256	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—urinary bladder cancer	3.98e-05	0.000254	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—urinary bladder cancer	3.97e-05	0.000254	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—urinary bladder cancer	3.97e-05	0.000254	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.94e-05	0.000252	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—urinary bladder cancer	3.92e-05	0.00025	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—urinary bladder cancer	3.9e-05	0.000249	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.89e-05	0.000249	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—urinary bladder cancer	3.89e-05	0.000248	CcSEcCtD
Dasatinib—Pain—Epirubicin—urinary bladder cancer	3.86e-05	0.000246	CcSEcCtD
Dasatinib—Constipation—Epirubicin—urinary bladder cancer	3.86e-05	0.000246	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—urinary bladder cancer	3.83e-05	0.000244	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—urinary bladder cancer	3.81e-05	0.000243	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—urinary bladder cancer	3.81e-05	0.000243	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.8e-05	0.000243	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—urinary bladder cancer	3.78e-05	0.000241	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—urinary bladder cancer	3.72e-05	0.000238	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—urinary bladder cancer	3.72e-05	0.000237	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—urinary bladder cancer	3.71e-05	0.000237	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.69e-05	0.000236	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—urinary bladder cancer	3.67e-05	0.000235	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—urinary bladder cancer	3.63e-05	0.000232	CcSEcCtD
Dasatinib—ABCB1—lymph node—urinary bladder cancer	3.62e-05	0.000284	CbGeAlD
Dasatinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.6e-05	0.00023	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—urinary bladder cancer	3.6e-05	0.00023	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—urinary bladder cancer	3.58e-05	0.000229	CcSEcCtD
Dasatinib—Pain—Doxorubicin—urinary bladder cancer	3.57e-05	0.000228	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—urinary bladder cancer	3.57e-05	0.000228	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—urinary bladder cancer	3.57e-05	0.000228	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—urinary bladder cancer	3.57e-05	0.000228	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—urinary bladder cancer	3.55e-05	0.000227	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—urinary bladder cancer	3.46e-05	0.000221	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.44e-05	0.00022	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.41e-05	0.000218	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—urinary bladder cancer	3.41e-05	0.000218	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—urinary bladder cancer	3.32e-05	0.000212	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—urinary bladder cancer	3.32e-05	0.000212	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—urinary bladder cancer	3.3e-05	0.000211	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—urinary bladder cancer	3.3e-05	0.000211	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—urinary bladder cancer	3.3e-05	0.000211	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—urinary bladder cancer	3.24e-05	0.000207	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—urinary bladder cancer	3.19e-05	0.000204	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—urinary bladder cancer	3.19e-05	0.000204	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—urinary bladder cancer	3.09e-05	0.000197	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.08e-05	0.000196	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—urinary bladder cancer	3.06e-05	0.000196	CcSEcCtD
Dasatinib—Rash—Methotrexate—urinary bladder cancer	3.04e-05	0.000194	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—urinary bladder cancer	3.04e-05	0.000194	CcSEcCtD
Dasatinib—Headache—Methotrexate—urinary bladder cancer	3.02e-05	0.000193	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—urinary bladder cancer	2.99e-05	0.000191	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—urinary bladder cancer	2.98e-05	0.00019	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—urinary bladder cancer	2.95e-05	0.000189	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—urinary bladder cancer	2.87e-05	0.000183	CcSEcCtD
Dasatinib—Nausea—Methotrexate—urinary bladder cancer	2.86e-05	0.000183	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—urinary bladder cancer	2.86e-05	0.000182	CcSEcCtD
Dasatinib—Rash—Epirubicin—urinary bladder cancer	2.84e-05	0.000182	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—urinary bladder cancer	2.84e-05	0.000181	CcSEcCtD
Dasatinib—Headache—Epirubicin—urinary bladder cancer	2.83e-05	0.00018	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—urinary bladder cancer	2.76e-05	0.000176	CcSEcCtD
Dasatinib—Nausea—Epirubicin—urinary bladder cancer	2.68e-05	0.000171	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—urinary bladder cancer	2.65e-05	0.000169	CcSEcCtD
Dasatinib—Rash—Doxorubicin—urinary bladder cancer	2.63e-05	0.000168	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—urinary bladder cancer	2.63e-05	0.000168	CcSEcCtD
Dasatinib—Headache—Doxorubicin—urinary bladder cancer	2.61e-05	0.000167	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—urinary bladder cancer	2.48e-05	0.000158	CcSEcCtD
Dasatinib—SRC—Immune System—IL2—urinary bladder cancer	1.78e-06	9.88e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—urinary bladder cancer	1.78e-06	9.87e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—urinary bladder cancer	1.78e-06	9.84e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—KRAS—urinary bladder cancer	1.78e-06	9.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—urinary bladder cancer	1.77e-06	9.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RHOA—urinary bladder cancer	1.77e-06	9.82e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—urinary bladder cancer	1.77e-06	9.79e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—urinary bladder cancer	1.77e-06	9.79e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—urinary bladder cancer	1.76e-06	9.74e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—SRC—urinary bladder cancer	1.76e-06	9.73e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—urinary bladder cancer	1.76e-06	9.73e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—urinary bladder cancer	1.75e-06	9.71e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—CDKN1A—urinary bladder cancer	1.75e-06	9.71e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—urinary bladder cancer	1.75e-06	9.71e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—urinary bladder cancer	1.75e-06	9.69e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—urinary bladder cancer	1.75e-06	9.68e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—urinary bladder cancer	1.75e-06	9.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ESR1—urinary bladder cancer	1.73e-06	9.6e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.73e-06	9.57e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—urinary bladder cancer	1.73e-06	9.56e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	1.72e-06	9.5e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—urinary bladder cancer	1.71e-06	9.48e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—urinary bladder cancer	1.71e-06	9.46e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EP300—urinary bladder cancer	1.71e-06	9.46e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—urinary bladder cancer	1.71e-06	9.44e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.7e-06	9.41e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CDKN1A—urinary bladder cancer	1.7e-06	9.41e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	1.7e-06	9.4e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—urinary bladder cancer	1.7e-06	9.39e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	1.7e-06	9.38e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—urinary bladder cancer	1.69e-06	9.37e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—urinary bladder cancer	1.68e-06	9.32e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—CDKN1A—urinary bladder cancer	1.68e-06	9.31e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.68e-06	9.31e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—urinary bladder cancer	1.68e-06	9.29e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—urinary bladder cancer	1.68e-06	9.27e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—urinary bladder cancer	1.67e-06	9.24e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EP300—urinary bladder cancer	1.67e-06	9.24e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—urinary bladder cancer	1.67e-06	9.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL8—urinary bladder cancer	1.66e-06	9.21e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—urinary bladder cancer	1.66e-06	9.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—urinary bladder cancer	1.66e-06	9.2e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—SRC—urinary bladder cancer	1.66e-06	9.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—urinary bladder cancer	1.66e-06	9.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—urinary bladder cancer	1.64e-06	9.09e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL8—urinary bladder cancer	1.64e-06	9.07e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—urinary bladder cancer	1.63e-06	9.03e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.63e-06	9.02e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.63e-06	9.01e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—urinary bladder cancer	1.62e-06	8.99e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	1.62e-06	8.99e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—SRC—urinary bladder cancer	1.62e-06	8.99e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	1.62e-06	8.96e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EP300—urinary bladder cancer	1.62e-06	8.95e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—urinary bladder cancer	1.61e-06	8.94e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EP300—urinary bladder cancer	1.6e-06	8.86e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—urinary bladder cancer	1.59e-06	8.8e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	1.58e-06	8.76e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—urinary bladder cancer	1.58e-06	8.75e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.58e-06	8.75e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.58e-06	8.74e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—urinary bladder cancer	1.58e-06	8.73e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SRC—urinary bladder cancer	1.57e-06	8.71e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—urinary bladder cancer	1.56e-06	8.66e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.56e-06	8.65e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.56e-06	8.65e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—urinary bladder cancer	1.56e-06	8.64e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—urinary bladder cancer	1.56e-06	8.63e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.56e-06	8.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.56e-06	8.62e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—urinary bladder cancer	1.56e-06	8.62e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1A—urinary bladder cancer	1.55e-06	8.6e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	1.55e-06	8.6e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—urinary bladder cancer	1.55e-06	8.58e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—urinary bladder cancer	1.55e-06	8.58e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	1.55e-06	8.57e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—urinary bladder cancer	1.55e-06	8.56e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—urinary bladder cancer	1.54e-06	8.54e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—urinary bladder cancer	1.54e-06	8.53e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—urinary bladder cancer	1.54e-06	8.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	1.54e-06	8.51e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—urinary bladder cancer	1.53e-06	8.5e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	1.53e-06	8.48e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	1.53e-06	8.46e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—urinary bladder cancer	1.53e-06	8.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CREBBP—urinary bladder cancer	1.52e-06	8.41e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.51e-06	8.36e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—urinary bladder cancer	1.51e-06	8.36e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—urinary bladder cancer	1.51e-06	8.34e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—urinary bladder cancer	1.5e-06	8.33e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—urinary bladder cancer	1.5e-06	8.32e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1—urinary bladder cancer	1.5e-06	8.31e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.5e-06	8.3e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.5e-06	8.28e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—urinary bladder cancer	1.5e-06	8.28e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—urinary bladder cancer	1.49e-06	8.26e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—EP300—urinary bladder cancer	1.49e-06	8.24e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—urinary bladder cancer	1.49e-06	8.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—urinary bladder cancer	1.49e-06	8.24e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—urinary bladder cancer	1.49e-06	8.23e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.48e-06	8.21e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—urinary bladder cancer	1.48e-06	8.2e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EP300—urinary bladder cancer	1.48e-06	8.18e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.48e-06	8.17e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—urinary bladder cancer	1.47e-06	8.15e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—urinary bladder cancer	1.47e-06	8.13e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.47e-06	8.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	1.46e-06	8.07e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—urinary bladder cancer	1.46e-06	8.06e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—urinary bladder cancer	1.46e-06	8.06e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—urinary bladder cancer	1.45e-06	8.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—urinary bladder cancer	1.45e-06	8.03e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	1.44e-06	7.96e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—urinary bladder cancer	1.43e-06	7.92e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EP300—urinary bladder cancer	1.43e-06	7.9e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—urinary bladder cancer	1.43e-06	7.9e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.42e-06	7.89e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—urinary bladder cancer	1.42e-06	7.88e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—urinary bladder cancer	1.42e-06	7.88e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1A—urinary bladder cancer	1.42e-06	7.87e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.42e-06	7.86e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—urinary bladder cancer	1.42e-06	7.85e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	1.42e-06	7.84e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—urinary bladder cancer	1.41e-06	7.82e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—urinary bladder cancer	1.41e-06	7.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—urinary bladder cancer	1.41e-06	7.79e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EP300—urinary bladder cancer	1.4e-06	7.77e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.4e-06	7.77e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—urinary bladder cancer	1.4e-06	7.76e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—urinary bladder cancer	1.4e-06	7.75e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—urinary bladder cancer	1.39e-06	7.68e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.38e-06	7.64e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—urinary bladder cancer	1.38e-06	7.63e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.38e-06	7.62e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—urinary bladder cancer	1.38e-06	7.61e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RHOA—urinary bladder cancer	1.37e-06	7.61e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—urinary bladder cancer	1.37e-06	7.6e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—urinary bladder cancer	1.37e-06	7.58e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—urinary bladder cancer	1.37e-06	7.56e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—urinary bladder cancer	1.36e-06	7.55e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	1.36e-06	7.55e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.36e-06	7.51e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—urinary bladder cancer	1.35e-06	7.5e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—urinary bladder cancer	1.35e-06	7.49e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	1.35e-06	7.45e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—urinary bladder cancer	1.34e-06	7.44e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—urinary bladder cancer	1.33e-06	7.39e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—urinary bladder cancer	1.31e-06	7.28e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.31e-06	7.27e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—urinary bladder cancer	1.31e-06	7.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—urinary bladder cancer	1.3e-06	7.22e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—urinary bladder cancer	1.3e-06	7.21e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—urinary bladder cancer	1.3e-06	7.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—urinary bladder cancer	1.3e-06	7.19e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—urinary bladder cancer	1.29e-06	7.14e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—urinary bladder cancer	1.29e-06	7.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—urinary bladder cancer	1.27e-06	7.05e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	1.27e-06	7.03e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	1.27e-06	7.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.26e-06	6.98e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—urinary bladder cancer	1.26e-06	6.97e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.26e-06	6.95e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.25e-06	6.9e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.25e-06	6.9e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—urinary bladder cancer	1.24e-06	6.88e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	1.24e-06	6.87e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—urinary bladder cancer	1.24e-06	6.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	1.23e-06	6.83e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	1.23e-06	6.8e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	1.23e-06	6.79e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—urinary bladder cancer	1.22e-06	6.77e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—urinary bladder cancer	1.22e-06	6.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—urinary bladder cancer	1.22e-06	6.73e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—urinary bladder cancer	1.21e-06	6.68e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—urinary bladder cancer	1.2e-06	6.63e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.19e-06	6.61e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—urinary bladder cancer	1.19e-06	6.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—urinary bladder cancer	1.18e-06	6.52e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	1.17e-06	6.49e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.17e-06	6.49e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—urinary bladder cancer	1.17e-06	6.47e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—urinary bladder cancer	1.17e-06	6.47e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.17e-06	6.46e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—urinary bladder cancer	1.16e-06	6.44e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—urinary bladder cancer	1.16e-06	6.41e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—urinary bladder cancer	1.15e-06	6.39e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—urinary bladder cancer	1.15e-06	6.38e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-06	6.36e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—urinary bladder cancer	1.14e-06	6.33e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—urinary bladder cancer	1.14e-06	6.3e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—urinary bladder cancer	1.14e-06	6.29e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—urinary bladder cancer	1.13e-06	6.26e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—urinary bladder cancer	1.12e-06	6.22e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.12e-06	6.2e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—urinary bladder cancer	1.11e-06	6.13e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	1.1e-06	6.1e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.1e-06	6.1e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—urinary bladder cancer	1.1e-06	6.07e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—urinary bladder cancer	1.09e-06	6.04e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—urinary bladder cancer	1.09e-06	6.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—urinary bladder cancer	1.09e-06	6.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—urinary bladder cancer	1.09e-06	6.01e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.08e-06	5.95e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—urinary bladder cancer	1.07e-06	5.95e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.05e-06	5.8e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	1.04e-06	5.77e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—urinary bladder cancer	1.04e-06	5.73e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—urinary bladder cancer	1.02e-06	5.65e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—urinary bladder cancer	1.02e-06	5.64e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.02e-06	5.63e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—urinary bladder cancer	1.01e-06	5.6e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—urinary bladder cancer	1e-06	5.56e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	9.97e-07	5.52e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	9.96e-07	5.52e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—urinary bladder cancer	9.76e-07	5.4e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	9.73e-07	5.39e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	9.7e-07	5.37e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—urinary bladder cancer	9.68e-07	5.36e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	9.62e-07	5.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	9.62e-07	5.33e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—urinary bladder cancer	9.61e-07	5.32e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—urinary bladder cancer	9.61e-07	5.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—urinary bladder cancer	9.55e-07	5.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	9.41e-07	5.21e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—urinary bladder cancer	9.25e-07	5.12e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.22e-07	5.1e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—urinary bladder cancer	9.17e-07	5.08e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—urinary bladder cancer	9.14e-07	5.06e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.05e-07	5.01e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—urinary bladder cancer	9.02e-07	4.99e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	8.94e-07	4.95e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—urinary bladder cancer	8.82e-07	4.88e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.81e-07	4.87e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	8.58e-07	4.75e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.5e-07	4.71e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—urinary bladder cancer	8.37e-07	4.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—urinary bladder cancer	8.33e-07	4.61e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	8e-07	4.43e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.68e-07	4.25e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—urinary bladder cancer	7.41e-07	4.1e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—urinary bladder cancer	7.32e-07	4.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—urinary bladder cancer	7.08e-07	3.92e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	7.03e-07	3.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.9e-07	3.82e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.62e-07	3.67e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	6.13e-07	3.39e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.85e-07	3.24e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.42e-07	3e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.73e-07	2.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.51e-07	2.5e-06	CbGpPWpGaD
